CLINICAL_TRIALS
withdrawal
· 2018-01-25
Clinical Trial Update: COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF [Phase 3]
Summary
Phase 3 trial investigating colchicine to prevent recurrence of atrial fibrillation after electrical cardioversion was withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Elpen Pharmaceutical Co. Inc. | Conditions: Atrial Fibrillation | Phase 3 | Status: WITHDRAWN